Omicron variants bind to human angiotensin-converting enzyme 2 (ACE2) much stronger due to higher number of charged-charged interactions
Affiliation:
1. Izmir Biomedicine and Genome Center
Abstract
Since the start of COVID-19 pandemic, several mutant variants of SARS-CoV-2 have emerged with different virulence and transmissibility patterns. Some of these variants have been labeled as variants of concern (VOC). There are mainly five strain clades with VOC status: Alpha, Beta, Gamma, Delta, and Omicron. Omicron sub-variants have been currently in circulation around the world, and they show faster transmissibility and lower virulence compared to others. Receptor binding domain (RBD) of SARS-CoV-2 spike protein is the region where it binds to human angiotensin-converting enzyme 2 (hACE2) on the host cell. Mutations on RBD might have direct or indirect effects on differential disease patterns of these variants. In this study, we analyzed sequence and structures of SARS-CoV-2 variants’ RBD domains and documented their predicted affinities and contact interactions with hACE2. We found that Omicron sub-variants have much higher hACE2 affinities compared to other VOC strains. To understand reasons behind this, we checked biophysical characteristics of RBD-hACE2 contacts. Surprisingly, number of charged-charged interactions of Omicron sub-variants were on average 4-fold higher. These higher charged residue mutations on epitope region of Omicron sub-variants leading to stronger affinity for hACE2 might shed light onto why Omicron has less severe disease symptoms.
Publisher
Field Crops Central Research Institute
Reference28 articles.
1. Aleem, A., Akbar Samad, A. B., & Slenker, A. K. (2022). Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/34033342 2. Are, E. B., Song, Y., Stockdale, J. E., Tupper, P., & Colijn, C. (2023). COVID-19 endgame: From pandemic to endemic? Vaccination, reopening and evolution in low- and high-vaccinated populations. J Theor Biol, 559, 111368. https://doi.org/10.1016/j.jtbi.2022.111368 3. Barton, M. I., MacGowan, S. A., Kutuzov, M. A., Dushek, O., Barton, G. J., & van der Merwe, P. A. (2021). Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife, 10. https://doi.org/10.7554/eLife.70658 4. Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023). A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses, 15(1). https://doi.org/10.3390/v15010167 5. Das, S., Samanta, S., Banerjee, J., Pal, A., Giri, B., Kar, S. S., & Dash, S. K. (2022). Is Omicron the end of pandemic or start of a new innings? Travel Med Infect Dis, 48, 102332. https://doi.org/10.1016/j.tmaid.2022.102332
|
|